M&A / Deals Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout Pharmaceutical TechnologyBiogen's acquisition of Apellis Pharmaceuticals will add Syfovre and Empaveli to the latter company's portfolio of medicines.M&A / DealsRare DiseaseRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaceutical Technology Biogen’s acquisition of Apellis Pharmaceuticals will add Syfovre and Empaveli to the latter company’s portfolio of medicines. M&A / DealsRare DiseaseRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Telomir seeks FDA approval for Telomir-1 to treat breast cancerNext: Agios mulls early FDA filing for sickle cell therapy Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
